CVS Health, Eli Lilly, and MinuteClinic are collaborating on a program to provide patient access to FDA-approved GLP-1 therapies through digital weight loss visits.
3 reports, 2 independent
Updated Aug 7
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CVS Health, Eli Lilly, and MinuteClinic are collaborating on a program to provide patient access to FDA-approved GLP-1 therapies through digital weight loss visits.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CVS Health, Eli Lilly, and MinuteClinic collaborate on GLP-1 patient access program.1 source
CVS and MinuteClinic integrate into a connected care network, improving patient access via DTC collaboration.1 source
Keep exploring
The entities involved
-
CVS Health
company
-
Eli Lilly and Company
American pharmaceutical company
Related events
- GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.